UBS lowered the firm’s price target on Jasper Therapeutics (JSPR) to $25 from $29 and keeps a Buy rating on the shares. Jasper’s Q2 print was “straightforward,” while the focus turns to the critical BEACON data in Q4, the analyst tells investors in a research note.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JSPR:
- Hold Rating on Jasper Therapeutics Amid Uncertainty in BEACON Study and Drug Development Timeline
- Jasper Therapeutics Faces Business Risks Amid Clinical Trial Delays and Competitive Pressures
- Jasper Therapeutics: Promising Clinical Data and Strategic Focus Drive Buy Rating
- Jasper Therapeutics Reports Promising Q2 2025 Results
- Jasper Therapeutics reports Q2 EPS ($1.74), consensus ($1.33)